Veracyte, Inc. (VCYT): Price and Financial Metrics


Veracyte, Inc. (VCYT): $46.40

-0.13 (-0.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

VCYT POWR Grades


  • Sentiment is the dimension where VCYT ranks best; there it ranks ahead of 67.27% of US stocks.
  • The strongest trend for VCYT is in Momentum, which has been heading down over the past 52 weeks.
  • VCYT ranks lowest in Momentum; there it ranks in the 10th percentile.

VCYT Stock Summary

  • VCYT's price/sales ratio is 19.94; that's higher than the P/S ratio of 90.02% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for Veracyte Inc; that's greater than it is for merely 6.8% of US stocks.
  • Veracyte Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -25.55%, greater than the shareholder yield of only 11.36% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Veracyte Inc, a group of peers worth examining would be XGN, SPNE, AWH, TELA, and HAE.
  • Visit VCYT's SEC page to see the company's official filings. To visit the company's web site, go to www.veracyte.com.

VCYT Valuation Summary

  • VCYT's price/earnings ratio is -51.5; this is 241.1% lower than that of the median Healthcare stock.
  • VCYT's price/sales ratio has moved down 3 over the prior 95 months.
  • Over the past 95 months, VCYT's price/sales ratio has gone down 3.

Below are key valuation metrics over time for VCYT.

Stock Date P/S P/B P/E EV/EBIT
VCYT 2021-08-31 20.6 3.3 -51.5 -43.9
VCYT 2021-08-30 20.9 3.4 -52.1 -44.5
VCYT 2021-08-27 20.4 3.3 -51.0 -43.5
VCYT 2021-08-26 19.0 3.1 -47.5 -40.2
VCYT 2021-08-25 19.0 3.1 -47.5 -40.2
VCYT 2021-08-24 18.0 2.9 -45.0 -37.8

VCYT Growth Metrics

  • Its 4 year price growth rate is now at 419.69%.
  • Its 5 year net cashflow from operations growth rate is now at 72.1%.
  • The 5 year net income to common stockholders growth rate now stands at 33.54%.
Over the past 30 months, VCYT's revenue has gone up $65,457,000.

The table below shows VCYT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 157.465 -34.661 -63.074
2021-03-31 123.064 -44.971 -65.061
2020-12-31 117.483 -9.711 -34.909
2020-09-30 112.677 -10.182 -34.323
2020-06-30 112.529 -13.49 -30.929
2020-03-31 121.961 -7.522 -22.398

VCYT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCYT has a Quality Grade of D, ranking ahead of 18.69% of graded US stocks.
  • VCYT's asset turnover comes in at 0.213 -- ranking 68th of 81 Healthcare stocks.
  • CHE, HCSG, and NTRA are the stocks whose asset turnover ratios are most correlated with VCYT.

The table below shows VCYT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.213 0.673 -1.427
2021-03-31 0.224 0.662 -1.543
2020-12-31 0.327 0.647 -0.827
2020-09-30 0.360 0.642 -0.795
2020-06-30 0.425 0.652 -0.693
2020-03-31 0.462 0.670 -0.490

VCYT Price Target

For more insight on analysts targets of VCYT, see our VCYT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.17 Average Broker Recommendation 1.5 (Moderate Buy)

VCYT Stock Price Chart Interactive Chart >

Price chart for VCYT

VCYT Price/Volume Stats

Current price $46.40 52-week high $86.03
Prev. close $46.53 52-week low $32.87
Day low $45.66 Volume 218,700
Day high $47.35 Avg. volume 782,969
50-day MA $45.78 Dividend yield N/A
200-day MA $47.59 Market Cap 3.29B

Veracyte, Inc. (VCYT) Company Bio


Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.


VCYT Latest News Stream


Event/Time News Detail
Loading, please wait...

VCYT Latest Social Stream


Loading social stream, please wait...

View Full VCYT Social Stream

Latest VCYT News From Around the Web

Below are the latest news stories about Veracyte Inc that investors may wish to consider to help them evaluate VCYT as an investment opportunity.

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif., October 14, 2021--New data to be presented at ASTRO 2021 reinforce the clinical utility of Veracyte's Decipher Prostate genomic classifier

Yahoo | October 14, 2021

New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

SOUTH SAN FRANCISCO, Calif., October 13, 2021--Data published in the Journal of Urology demonstrate Veracyte’s Decipher Bladder test can identify tumors most likely to respond to chemotherapy

Yahoo | October 13, 2021

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

SOUTH SAN FRANCISCO, Calif., October 12, 2021--Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

Yahoo | October 12, 2021

How a simple nasal swab could help a Peninsula company redefine lung cancer risk

"We've been all over it," a Veracyte executive said about the company's research to detect lung cancer earlier and less invasively.

Yahoo | October 11, 2021

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

SOUTH SAN FRANCISCO, Calif., October 11, 2021--Data to be presented at CHEST show Veracyte's Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis.

Yahoo | October 11, 2021

Read More 'VCYT' Stories Here

VCYT Price Returns

1-mo -10.84%
3-mo 18.22%
6-mo -8.41%
1-year 24.26%
3-year 391.53%
5-year 470.02%
YTD -5.19%
2020 75.29%
2019 121.94%
2018 92.65%
2017 -15.63%
2016 7.50%

Continue Researching VCYT

Want to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:

Veracyte Inc (VCYT) Stock Price | Nasdaq
Veracyte Inc (VCYT) Stock Quote, History and News - Yahoo Finance
Veracyte Inc (VCYT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.888 seconds.